title: Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.
abstract: CTLA-4-deficient mice develop a lethal autoimmune lymphoproliferative disorder that is strictly dependent on in vivo CD28 costimulation. Nevertheless, it is not known whether there is a specific site on the CD28 molecule that is required for induction of autoimmunity. Using CTLA-4-deficient mice expressing CD28 molecules with various point mutations in the CD28 cytosolic tail, the present study documents that in vivo costimulation for induction of autoimmune disease strictly requires an intact C-terminal proline motif that promotes lymphocyte-specific protein tyrosine kinase Lck binding to the CD28 cytosolic tail, because point mutations in C-terminal proline residues (Pro-187 and Pro-190) completely prevented disease induction. In contrast, in vivo costimulation for disease induction did not require either an intact YMNM motif or an intact N-terminal proline motif, which, respectively, promote phosphoinositide 3-kinase and IL2-inducible T cell kinase binding to the CD28 cytosolic tail. Thus, in vivo CD28 costimulation for induction of autoimmune disease is strictly and specifically dependent on an intact C-terminal proline motif that serves as a lymphocyte-specific protein tyrosine Lck kinase binding site in the CD28 cytosolic tail.
authors: Experimental Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
authors: Xuguang
authors: X
authors: Tai
authors: Francois
authors: F
authors: Van Laethem
authors: Arlene H
authors: AH
authors: Sharpe
authors: Alfred
authors: A
authors: Singer
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism*; D000943:Antigens, Differentiation / Q000235:genetics / Q000378:metabolism*; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D001665:Binding Sites; D018106:CD28 Antigens / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D060908:CTLA-4 Antigen; D051379:Mice; D018345:Mice, Knockout; D008969:Molecular Sequence Data; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D015996:Survival Rate
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D015703:Antigens, CD; D000943:Antigens, Differentiation; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; C402726:Sh2d2a protein, mouse
references: Science. 1993 Jul 30;261(5121):609-12
references: 7688139
references: Nat Immunol. 2004 Apr;5(4):435-42
references: 15004555
references: Nature. 1994 May 26;369(6478):327-9
references: 8183372
references: Eur J Immunol. 1995 Apr;25(4):1044-50
references: 7737275
references: Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8891-5
references: 7568038
references: Science. 1995 Nov 10;270(5238):985-8
references: 7481803
references: Immunity. 1995 Nov;3(5):541-7
references: 7584144
references: J Biol Chem. 1996 Apr 19;271(16):9403-9
references: 8621607
references: J Exp Med. 1996 Sep 1;184(3):931-43
references: 9064353
references: Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9296-301
references: 9256476
references: Eur J Immunol. 1997 Aug;27(8):1887-92
references: 9295023
references: J Immunol. 1997 Oct 1;159(7):3220-9
references: 9317120
references: Immunity. 1997 Nov;7(5):619-28
references: 9390686
references: J Biol Chem. 1998 Jan 2;273(1):296-301
references: 9417079
references: J Biol Chem. 1998 Aug 14;273(33):21194-202
references: 9694876
references: Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8603-8
references: 10411922
references: J Exp Med. 1999 Aug 2;190(3):375-84
references: 10430626
references: J Immunol. 1999 Nov 1;163(9):5029-38
references: 10528208
references: Nat Immunol. 2005 Feb;6(2):152-62
references: 15640801
references: J Exp Med. 2006 Sep 4;203(9):2121-33
references: 16908623
references: Immunity. 2000 Apr;12(4):431-40
references: 10795741
references: J Immunol. 2000 Jun 1;164(11):5805-14
references: 10820259
references: J Immunol. 2001 Mar 15;166(6):3797-803
references: 11238622
references: Nat Immunol. 2001 Apr;2(4):325-32
references: 11276203
references: J Clin Invest. 2001 Apr;107(7):881-7
references: 11285307
references: J Immunol. 2001 May 1;166(9):5331-5
references: 11313368
references: Nat Immunol. 2002 Mar;3(3):259-64
references: 11828322
references: Nat Rev Immunol. 2003 Jul;3(7):544-56
references: 12876557
references: Nat Rev Immunol. 2003 Dec;3(12):939-51
references: 14647476
references: J Exp Med. 1993 Nov 1;178(5):1701-12
references: 8228817